CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 23 enrolled
Drug / intervention
Cosyntropin +1 moredrug
Likely dose
Cosyntropin 70 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02339506
NCT02339506N/ACompleted

Stress and the Nervous System

Brigham and Women's Hospital·interventional·Posted Jan 15, 2015·Updated Dec 3, 2025

In Brief

A clinical study evaluating Cosyntropin and Placebo for Autonomic Nervous System and 2 related conditions. Completed, enrolled 23 participants across 1 site.

Detailed Summary

Models of stress such as hypoglycemia have identified that stress results the next day in decreased baroreflex sensitivity. This project will test the hypothesis that these delayed changes in autonomic nervous system function are secondary to a rise in ACTH. The investigators will infuse cosyntropin versus placebo in a double-blind, crossover study in healthy adults and measure the delayed effects on the autonomic system as measured by cardiovagal baroreflex sensitivity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 15, 2015
Enrollment StartApr 1, 2015
Primary CompletionOct 1, 2016
Study CompletionNov 1, 2020
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11.5 years ago

Interventions

Cosyntropindrug

Subjects will receive cosyntropin at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.

Placebodrug

Subjects will receive placebo (normal saline infusion) for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.